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Abstract
Background: Reports of severe cases and increasing levels of drug resistance highlight the importance of
improved Plasmodium vivax case management. Whereas monitoring P. vivax resistance to anti-malarial drug by in
vivo and in vitro tests remain challenging, molecular markers of resistance represent a valuable tool for high-scale
analysis and surveillance studies. A new high-throughput assay for detecting the most relevant markers related to
P. vivax drug resistance was developed and assessed on Papua New Guinea (PNG) patient isolates.
Methods: Pvdhfr, pvdhps and pvmdr1 fragments were amplified by multiplex nested PCR. Then, PCR products were
processed through an LDR-FMA (ligase detection reaction - fluorescent microsphere assay). 23 SNPs, including
pvdhfr 57-58-61 and 173, pvdhps 382-383, 553, 647 and pvmdr1 976, were simultaneously screened in 366 PNG P.
vivax samples.
Results: Genotyping was successful in 95.4% of the samples for at least one gene. The coexistence of multiple
distinct haplotypes in the parasite population necessitated the introduction of a computer-assisted approach to
data analysis. Whereas 73.1% of patients were infected with at least one wild-type genotype at codons 57, 58 and
61 of pvdhfr, a triple mutant genotype was detected in 65.6% of the patients, often associated with the 117T
mutation. Only one patient carried the 173L mutation. The mutant 647P pvdhps genotype allele was approaching
genetic fixation (99.3%), whereas 35.1% of patients were infected with parasites carrying the pvmdr1 976F mutant
allele.
Conclusions: The LDR-FMA described here allows a discriminant genotyping of resistance alleles in the pvdhfr,
pvdhps, and pvmdr1 genes and can be used in large-scale surveillance studies.
Background
Plasmodium vivax is the most widespread of the malaria
parasites infecting human hosts and may be responsible
for up to 400 million infections each year [1,2]. The
widespread belief that this parasite causes only benign
malaria has been challenged recently by reports of
severe pathology, including cerebral malaria, acute
respiratory distress, acute renal failure, and severe
anaemia in patients with P. vivax infections [3-6]. In
addition, there are increasing worldwide reports of treat-
ment failure after administration of the standard drug
regimens, mainly chloroquine (CQ) [7-15]. New drugs
are now available, but they are significantly more costly
than CQ plus primaquine, the standard treatment for
vivax malaria for the last 50 years [16]. In order to
change their treatment policies based on local evidence,
countries need efficient methods to assess potential for
resistance to current standard treatments.
Monitoring in vivo drug resistance remains challen-
ging due to the ability of P. vivax to relapse from long-
lasting liver stages. At the same time, the recurrence of
parasitaemia due to de novo infection can confound
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infections [17] makes it possible to distinguish infection
by parasites with different genotypes (new infections)
[18,19] from infection by parasites with identical geno-
types (whether due to relapse or to recrudescence from
blood-stage parasites that survived drug treatment) [20].
Of course, even molecular diagnosis cannot distinguish
persistent infection from de novo infection by a geneti-
cally identical parasite. In vitro assays, which should
provide drug susceptibility data free from the effects of
confounding factors, such as host immunity, are still dif-
ficult to conduct because of the lack of stable, continu-
ous P. vivax in vitro culture [5,21]. Molecular markers
of resistance, therefore, represent a useful tool to moni-
tor the introduction and spread of anti-malarial resis-
tance. For P. vivax, these markers include mutations in
genes encoding the dihydrofolate reductase (PvDHFR)
and the dihydropteroate synthase (PvDHPS) that are
involved in drug resistance to antifolates (pyrimetha-
mine) [22], and sulphonamides (sulphadoxine) [23],
respectively. The 976F mutation in the gene encoding
the multidrug resistance 1 protein (PvMDR1), which has
been associated with 4-aminoquinolines (amodiaquine,
CQ) resistance in some [21,24] but not all studies
[21,25].
Further investigations are needed to assess the predic-
tive value of molecular markers; their use in monitoring
of P. vivax drug resistance needs to be addressed, geo-
graphically, at both a local and a large-scale level [26].
For these reasons, a new assay was developed to detect
single nucleotide polymorphisms (SNPs) potentially
associated with P. vivax drug resistance, in pvdhfr,
pvdhps and pvmdr1 genes (total of 23 allelic variants).
This post-PCR multiplex assay uses ligase detection
reaction and fluorescent-microsphere technologies. A
similar approach was previously developed to screen for
Plasmodium falciparum drug resistance-associated SNPs
[27]. The assay was validated using sequenced isolates
and a subset of samples from Papua New Guinea
(PNG), where CQ resistant P. vivax was first described
in 1989 [12]. Resistance to sulphadoxine-pyrimethamine
(SP) was observed to be low until 2000 [28], when PNG
introduced CQ or amodiaquine plus SP as the national
first line treatment for both P. falciparum and P. vivax.
Since then, levels of resistance to this combination have
increased [24,29]. Here the development and application
of this multiplex assay is described; the frequency of P.
vivax genetic markers associated with multiple drug
resistance in PNG patient isolates is presented.
Methods
Study population and blood sample collection
Samples were collected between 2006 and 2007 through
active detection of malaria infections in a cohort of
children 1-4 yrs of age in Ilaita, East Sepik Province,
Papua New Guinea [30]. The study was approved by the
PNG Medical Research Advisory Council. Plasmodium
vivax infected monkey blood (SalI and Thai-3 strains)
was kindly provided by W. E. Collins (Centers for Dis-
ease Control and Prevention, Atlanta, GA). Plasmodium
falciparum positive samples were obtained from a cul-
ture of the 3D7 strain.
DNA template preparation
DNA was extracted from cell pellets (250μL) using the
QIAamp 96 DNA blood kit (Qiagen, Valencia, CA).
Genomic DNA was extracted from P. vivax-infected
monkey blood or from P. falciparum culture using the
QIAamp DNA blood minikit (Qiagen, Valencia, CA).
Plasmodium species diagnosis
Plasmodium species diagnosis was performed using a
post-PCR ligase detection reaction - fluorescent micro-
sphere assay (LDR-FMA) as described previously
[30,31]. Positive samples for P. vivax infections were
identified and then assessed for mutations in pvdhfr,
pvdhps and pvmdr1 genes.
Multiplex PCR amplification of P. vivax dhfr, dhps and
mdr1 target sequences
A nested PCR was developed to perform multiplex
amplification of P. vivax dhfr, dhps and mdr1 target
sequences. All Nest 1 reactions were performed in a
buffer containing 3 pmol of each primer, 67 mM Tris-
HCl (pH = 8.8), 3.3 mM MgSO4,1 6 . 6m M( N H 4)2SO4,
10 mM mercaptoethanol, 100 μM (each) dATP, dGTP,
dCTP, dTTP, and 2.5 U of thermostable DNA polymer-
ase. Nest 2 reactions were performed with 3 μLo fP C R
products from the Nest 1 reaction using the same con-
ditions except for the primers (6 pmol). Primer
sequences and size of PCR products are given in Table
A1 (Additional file 1). PCR amplification was performed
under the following conditions: Nest 1 - 94°C for 2 min-
utes and 35 cycles at 94°C for 30 seconds, 60°C for 30
seconds, 72°C for 3 minutes, and a final extension at 72°
C for 5 minutes; Nest 2 - 94°C for 2 minutes and 45
cycles at 94°C for 30 seconds, 63°C for 30 seconds, 72°C
for 90 seconds, and a final extension at 72°C for 4 min-
utes. The specificity of the amplification was evaluated
following electrophoresis on a 2% agarose gel in 1× TBE
buffer (8.9 mM Tris, 8.9 mM boric acid, 2.0 mM
EDTA).
Ligase detection reaction - fluorescence microspheres
assay (LDR-FMA)
A description of the three-step, post-PCR LDR-FMA,
procedure has been provided in previous publications
[27,31]. After PCR amplification of pvdhfr, pvdhps and
Barnadas et al. Malaria Journal 2011, 10:282
http://www.malariajournal.com/content/10/1/282
Page 2 of 11pvmdr1 target sequences, products were subjected to a
ligase detection reaction between modified upstream
allele-specific and downstream conserved sequence pri-
mers. Modifications included the addition of unique
TAG sequences at the 5’ extremity of the upstream
sequence-specific primers and 5’ phosphorylation/3’ bio-
tinylation of the downstream primers. In a second step,
hybridization occurred between TAG and anti-TAG oli-
gonucleotide probes bound to fluorescent microspheres.
The products of this reaction were then incubated in a
solution containing streptavidin-phycoerythrin (SA-PE)
to allow binding to the 3’ biotin of the conserved
sequence primer.
One μL of multiplex PCR product was subjected to
the ligation reaction, performed in a solution (15μL)
containing 20 mM Tris-HCl buffer (pH 7.6), 25 mM
potassium acetate, 10 mM magnesium acetate, 1 mM
NAD
+, 10 mM dithiothreitol, 0.1% Triton X-100, 10 nM
(200 fmol) each LDR probe, 1 μl of each PCR product,
and 2 U of Taq DNA ligase (New England Biolabs, Bev-
erly, MA). Reaction mixtures were initially heated to 95°
C for 1 min, followed by 32 thermal cycles at 95°C for
15 s (denaturation) and 60.0°C for 2 min (annealing/
ligation). The multiplex LDR product (5μl) was then
added to 60μl of hybridization solution (3 M tetra-
methylammonium chloride [TMAC], 50 mM Tris-HCl
[pH 8.0], 3 mM EDTA [pH 8.0], 0.10% sodium dodecyl
sulfate) containing 250 Luminex FlexMAP™ micro-
spheres for each allelic set. Mixtures were heated to 95°
C for 90 s and incubated at 37°C for 40 min to allow
hybridization between SNP-specific LDR products and
microsphere-labelled anti-TAG probes. Following hybri-
dization, 6 μl of streptavidin-R-phycoerythrin (Molecular
Probes, Eugene, OR) in TMAC hybridization solution
(20 ng/μl) was added to the post-LDR mixture and incu-
bated at 37°C for 40 min in Costar 6511 M polycarbo-
nate 96-well V-bottom plates (Corning Inc., Corning,
NY). Detection of SNP-specific products (Classification
signal = microspheres fluorescence/Reporter signal =
SA-PE) was performed through a BioPlex liquid array
reader (Bio-Rad laboratories, Hercules, CA). All fluores-
cence data were compiled into Microsoft Excel spread-
sheets using Bio-Rad (Hercules, CA) software, Bio-Plex
Manager 4.1.
Sequences of LDR primers are given in Table A2
(Additional file 2). These primers were designed to
allow the detection of mutations at five pvdhfr codons
(57-58-61, 117, 173), four pvdhps codons (382-383, 553,
647) and one pvmdr1 codon (976), with a total of 23
SNPs detected. LDR primers were designed according to
available sequences published in the literature and
sequences obtained from PNG isolates. To improve the
specificity of the assay, a mismatch (G®A) was intro-
duced in the sequence of the primers (at nucleotide 178,
accession no. X98123.1) hybridizing against codons 57-
58-61 of pvdhfr gene. This allowed a decrease of the
allele-specific background observed.
Obtaining controls and sequencing
Pvdhfr, pvdhps and pvmdr1 genes were amplified by
nested PCR from a subset of samples (n = 6); individual
species-specific gene fragments were sequenced after
purification using the QIAquick PCR purification kit
(Qiagen, Valencia, CA). Additionally, six isolates (geno-
types known) kindly provided by D. Ménard (Pasteur
Institute, Madagascar) and C. Sibley (University of
Washington, Seattle, WA) were amplified for pvdhfr
gene; PCR products were cloned to obtain positive con-
trols for a selection of mutant pvdhfr genotypes: 57I
(ata), 58R (agg, aga, cgt), 117N/117T (aac/acc), 173L
(ctt). Three isolates were cloned in order to obtain
pvdhps wild type, single mutant 383G and double
mutant 382C-383G genotype controls, and two isolates
to obtain pvmdr1 Y976 and 976F. Cloning was per-
formed using a TOPO-TA vector cloning system, and
Top10F competent cells (Invitrogen), according to the
manufacturer’s instructions; DNA was extracted using
the QIAprep Spin Miniprep kit (Qiagen, Valencia, CA).
Sequencing reactions were performed by single-pass
bidirectional plasmid sequencing (Agencourt Bios-
ciences, Beverly, MA).
Results
Plasmodium vivax infections were observed in 366
(52%) of 704 samples evaluated by Plasmodium species
diagnosis with a post-PCR LDR-FMA [31]; 113 samples
(30.9%) were co-infected with P. falciparum.AL D R -
FMA multiplex marker analysis was developed to detect
SNPs in pvdhfr, pvdhps and pvmdr1 genes related to
anti-malarial drug resistance and used to genotype these
366 P. vivax samples.
Validation of the nested multiplex PCR approach for a
simultaneous amplification of pvdhfr, pvdhps and pvmdr1
genes
To improve the efficiency of the assay, a nested PCR
was performed. Three sets of primers were combined in
two-step multiplex PCR. Figure 1 shows the fragment
sizes obtained (amplification of P. vivax Sal-I and Thai-
3 strains, and one field isolate), following agarose gel
electrophoresis: 1423 bp for pvdhps,9 1 7b pf o rpvdhfr
and 545 bp for pvmdr1.A sm i x e dPlasmodium species
infections are commonly observed in PNG, specificity of
the amplification was checked using P. falciparum 3D7
genomic DNA. To evaluate the multiplex PCR amplifi-
cation strategy, a subset of samples (n = 39) were ana-
lysed to determine if all three target sequences were
amplified from all samples judged to be positive for P.
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these samples, 37 (95%) produced PCR products of the
expected sizes for the three gene-specific target
sequences using both single and multiplex PCR
strategies.
Validation of pvdhfr, pvdhps and pvmdr1 LDR-FMA probe
specificity
Sequenced isolates or clones were used to check the
specificity of LDR product formation and fluorescent
signals detected (Table A3, Additional file 3). At the
time of this study, a control template for the pvdhps
553G and 647P mutant alleles was not available.
Eight distinct pvdhfr haplotypes were discriminated
across codons 57, 58 and 61. Because of the proximity
of the three codons, haplotype-specific primers cover-
ing the three codons and displaying the different allele
combinations were designed. Results show that haplo-
type-specific background ranged from 168 to 3929
fluorescence units (FU); positive haplotype-specific sig-
nals ranged from 6968 to 25348 FU. Independently,
three alleles were discriminated at codon 117, with
allele-specific background ranging from 374 to 2740
FU, and positive allele-specific signals from 14942 to
24245 FU. Two alleles were discriminated at codon
173, with allele-specific background ranging from 566
to 8083 FU, and positive allele-specific signals from
19770 to 24564 FU.
Four pvdhps haplotypes were discriminated at codons
382 and 383 (using haplotype-specific primers). Results
show that allele-specific background ranged from 202 to
1798 FU; positive allele-specific signals ranged from
4925 to 21682 FU. Two pvmdr1 alleles were discrimi-
nated at codon 976. Results show that allele-specific
background ranged from 811 to 974 FU; positive allele-
specific signals ranged from 15634 to 19634 FU.
Similar to what was described elsewhere [32], at some
loci, an increase of the allele-specific background was
observed proportionally to the intensity of another
allele-specific signal (Figure 2). This effect was observed
on pvdhfr 57-58-61 FR(agg)T and pvdhfr 57-58-61 FR
(aga)T allele-specific backgrounds (when pvdhfr 57-58-
61 FST allele-specific signal was high), on pvdhfr 57-58-
61 LR(agg)T allele-specific background (when pvdhfr
57-58-61 LR(aga)T allele-specific signal was high) and
on pvdhfr 57-58-61 LR(agg)M allele-specific background
(when pvdhfr 57-58-61 LR(aga)M allele-specific signal
was high). A similar effect was observed on pvdhfr 173L
allele-specific background (when pvdhfr I173 allele-spe-
cific signal was high). A more moderate effect was
observed on pvdhps A647 allele-specific background
(when pvdhps 647P allele-specific signal was high).
Interpretation of the fluorescent signals using the polar/
multi-dimensional transformation of the data was thus
performed.
Computer-assisted multidimensional data analysis
The coexistence of multiple distinct haplotypes in the
parasite population necessitated the introduction of a
novel approach to the analysis of LDR-FMA datasets
from PNG.
Fluorescence signals from bi-allelic datasets were ana-
lysed using a polar transformation of the data in order
to improve the data analysis of Plasmodium polyclonal
infections, as previously described [32]. In the presence
of one allele, an increase of the reciprocal allelic SNP
signal can be observed, making direct determination of
a constant threshold for positivity (presence of the sec-
ond allele) inappropriate. Briefly, bivariate data were
transformed from Cartesian coordinates (x-axis = allele
X fluorescence signal; y-axis = allele Y fluorescence sig-
nal) into polar (r, θ) coordinates (here r =

x2 + y2 and
1 2  5  4  3 7  6   
dhps
dhfr 
mdr
Figure 1 Gel picture after nested multiplex amplification of pvdhfr, pvdhps and pvmdr1 fragments.1 :1 0 0b pD N Al a d d e r .2 :P. vivax
infected monkey blood (Thai 3). 3 P. vivax infected monkey blood (Sal1). 4: P. vivax positive PNG isolate. 5: P. falciparum 3d7. 6: Human DNA
(Plasmodium sp negative). 7: Blank (water).
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crosstalk interaction inducing the background signal. The
magnitude of the combined signal, r,r e p r e s e n t st h ed i s -
tance in the plane between a point (x,y) and the origin of
the graph. The angle, θ, between the x-axis and a ray
extending from the origin to the point (x,y) represents
the relative strength of the y versus the X signal. Samples
with θ≈0 correspond to pure infections of type X, sam-
ples with θ≈90° correspond to pure infections of type Y,
and intermediate values of θ representing samples with
polyclonal infections. Subsequently, the threshold analy-
sis included two steps. The first step determined a
threshold for positivity for infections. The set of samples
was divided into bins, from rmin to rmax, each having a
width of 100 fluorescence units (FU). The threshold of
positivity was determined as the value of r corresponding
to the bin containing the first minimum (in number of
counts) after the first maximum closest to r = 0. In addi-
tion, we require that the number of samples in the bin be
less than the number that would be expected under the
uniform distribution (for a full technical description of
the algorithm used for bi-allelic data please see [32]). The
second step of the threshold analysis discriminated
between polyclonal infections and allele-specific back-
ground signal. The set of samples was divided into 45
bins ranging from θ =0t oθ = π/2 radians (90°). The
threshold for the X+/Y- population was set at the first
minimum in the histogram as θ increased past the local
maximum close to θ = 0 (0°, or horizontal). The thresh-
old for the X-/Y+ population was set at the first mini-
mum in the histogram as θ decreased past the local
maximum close to θ = π/2 (90°, or vertical). Upon estab-
lishing the thresholds for distinguishing monoclonal ver-
sus polyclonal infections in the polar coordinate plane,
an inverse polar coordinate transformation returned the
data and the diagnosis threshold to the Cartesian plane.
Diagnosis of multi-allelic datasets (number of alleles >
2) was accomplished through a computer-assisted
procedure analogous to the polar transformation intro-
duced in DaRe et al [32]. Each sample was represented
as a vector  xi =

xi1,...,xij,...,xin

where the first
index (i), 1≤i≤N, represented the sample number (out of
N samples) and the index (j), 1≤j≤n represented the
allele (out of n alleles). For example, the data set for
pvdhfr locus 117 comprised n=3alleles and N = 366
samples; the data set for pvdhps loci 382-383 comprised
n=4alleles and N = 366 samples; the data set for
pvdhfr loci 57, 58 and 61 comprised n=8alleles and N
=3 6 6samples. The total magnitude of the fluorescence
signal for sample i was taken to be the Euclidean length
of the vector, Li =

n 
j=1
x2
ij . A histogram was constructed
of the N values of Li, using bins of width 100 fluores-
cence units, and the first minimum of the histogram
occurring after the first maximum was used as a diag-
nostic cut-off for distinguishing infected versus unin-
fected samples. Figure 3 shows the histogram of
fluorescence vector magnitudes for data from pvdhfr 57-
58-61, along with the threshold obtained. For each sam-
p l ew i t hv e c t o rm a g n i t u d ee x c e e d i n gt h ed i a g n o s t i c
magnitude threshold, the quantities aij=xij/Li were cal-
culated. These values, known as direction cosines,e q u a l
the cosine of the angle θij between the i
th vector  xi and
the j
th coordinate axis in n-dimensional space. When
the i
th sample is infected by parasites carrying at least
one allele, but not infected by parasites carrying the j
th
allele, the angle θij is close to 90 degrees because the
vector lies close to an (n-1)-dimensional subspace of the
n-dimensional space spanned by the (n-1) other vector
components. Consequently, the vector component xij is
significantly smaller than those representing the alleles
carried by infecting parasites, and the direction cosine
aij =c o s ( θij) will be close to zero. In order to assist the
practitioner in calling alleles, our data analysis code
(written in MATLAB) produces a histogram of all
Figure 2 Increase of the allele-specific background (F57 58R T61 allele signal) observed proportionally to the intensity of another
allele-specific signal (F57 S58 T61 allele signal).
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set. Figure 4 shows the histogram of direction cosines
produced for the pvdhfr 57-58-61 data set (n×Ninf =8×
338 = 2704 values).
Once the analysis code produced a histogram, we
inspected the histogram visually to identify appropriate
diagnostic cut-off values for the direction cosines.
Appropriate cut-offs were determined to be 0.20 for
pvdhfr 57-58-61, 0.16 for pvdhps 382-383, and 0.24 for
pvdhfr 117, see Figure 4, Additional files 4 and 5 (Figure
S2 and S4), respectively. Heuristically, the direction
cosine threshold was determined by identifying the max-
imum of the direction cosine histogram closest to aij =
0, and athresh, the location of the first minimum of the
histogram below that maximum, as determined by eye,
was used as the cut-off. Allele j in sample i was scored
as positive if aij>athresh,a n da snegative if aij≤ athresh.
Appropriate direction cosine thresholds for these data
sets ranged over 0.16≤a≤0.24, corresponding to angles
of approximately 75°-80°. Please see Figures S1-S4
(Additional files 4 and 5) for additional examples of the
magnitude and direction cosine histograms for multi-
allelic data sets.
Application of the LDR-FMA to PNG P. vivax samples
All three genes were successfully amplified and geno-
typed for 305 (83.3%) of the isolates. A positive result for
at least one gene associated with drug resistance (pvdhfr,
pvdhps or pvmdr1) was obtained for 349 (95.4%) of the
isolates in the first run. Of the isolates not successfully
genotyped 90% showed lower positivity with the Plasmo-
dium species diagnostic assay (500 to 10 000 FU).
Based on pvdhfr, pvdhps and pvmdr1 genotyping, a
monoclonal infection was found in only 70/305 (23.0%)
samples. The multiplicity of infection (MOI) was deter-
mined based on the maximum number of alleles
detected at one pvdhfr, pvdhps or pvmdr1 locus for each
isolate and estimated at 2.05 with pvdhfr displaying
more allelic combinations (MOI = 1.99) than pvdhps
(MOI = 1.03) and pvmdr1 (MOI = 1.29).
Figure 3 Histogram showing the distribution of fluorescence vector lengths{Li:1≤i≤N}f o ram u l t i - a l l e l i cd a t as e t( pvdhfr 57-58-61,
eight alleles). The dashed vertical line indicates the diagnosis threshold for infection vs. noninfection. Magnitude threshold = 1500; Ninf =338.
Histogram bin width = 100 fluorescence units. Inset panel shows magnified region near the diagnostic threshold, including small vertical blue
tick marks indicating the magnitudes for individual samples. Corresponding figures for pvdhps 382-383 (with four alleles) and for pvdhfr 117 (with
three alleles) are available as Figures S1 and S3, respectively (See Additional Files 4 and 5).
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37 isolates (52.9%) displayed a wild-type pvdhfr allele
(F57-S58-T61-S117-I173). The quadruple mutant geno-
type (57L-58R-61M-117T-I173) was found in 21 isolates
(30.0%); single (n = 2; 2.9%), and double (n = 10; 14.3%)
mutant genotypes were also observed (Table 1). All but
one of these samples displayed a single mutant type
pvdhps 647P allele, and 12 of them (17.1%) the pvmdr1
976F mutation.
When considering all infections (Table 2), the preva-
l e n c eo fm u l t i p l em u t a n tS N Ppvdhfr alleles was high.
Of 305 infected patients, 223 (73.1%) carried parasites
with a wild-type genotype at codons 57, 58 and 61,
whereas 200 (65.6%) displayed at least a triple mutant
genotype, most likely associated with the 117Tm u t a -
tion, as this mutation was found in the isolates infecting
206 (67.5%) patients. Only one patient carried parasites
with the 173L mutation. Interestingly, 303 parasite iso-
lates (99.3%) carried the mutant pvdhps 647P allele,
approaching genetic fixation. In contrast, mutant allelic
SNPs in codons 382 or 383 were found in the isolates
infecting two to three (0.7 to 1%) patients. The mutant
allele associated with P. vivax chloroquino-resistance,
pvmdr1 976F, was observed in 107 (35.1%) patient
isolates.
Discussion
Here is described a new high-throughput method to
detect SNPs associated with drug resistance of P. vivax,
simultaneously in pvdhfr, pvdhps and pvmdr1 genes. To
improve the efficiency of this assay, a nested PCR
approach was chosen which allowed a successful geno-
typing in 83.3% of the LDR-FMA P. vivax positive
samples.
Figure 4 Histograms showing the distribution of all Ninf×n direction cosine values. {aij:1≤i≤Ninf,1≤j≤n} for different multi-allelic data
sets. Only samples judged to be infected based on the magnitude histogram (see Figure 1) are included; the number of infected samples is
denoted Ninf, and the number of alleles for a given data set is denoted n. The dashed vertical line indicates the diagnosis threshold for infection
vs. noninfection of individual alleles. For the multi-allellic data sets, the thresholds were determined by visual inspection of the histograms. The
pvdhfr 57-58-61 data contained eight alleles, giving 338 × 8 = 2704 direction cosines total in the histogram; direction cosine threshold = 0.2.
Histogram bin width = 0.02. Inset panel shows magnified region near the diagnostic threshold, including small vertical blue tick marks indicating
the direction cosines for individual alleles. Corresponding figures for pvdhps 382-383 (with four alleles) and for pvdhfr 117 (with three alleles) are
available as Figures S2 and S4, respectively (See Additional Files 4 and 5).
Barnadas et al. Malaria Journal 2011, 10:282
http://www.malariajournal.com/content/10/1/282
Page 7 of 11The main challenge faced in developing this multi-
plexed assay was the interpretation of fluorescence data,
due to the simultaneous screening of multiple alleles at
one locus and the high level of polyclonality (up to four
isolates infecting a single patient). As described pre-
viously [32], an increase of background (or off-target)
fluorescent signal was consistently observed when PCR
amplification produced strong gene-specific fragments.
A polar transformation of the fluorescent data measured
was performed for bi-allelic datasets; the usefulness of
this transformation has been shown before [32]. In con-
trast, datasets with more than two alleles present
required a multidimensional transformation of the data,
based on the same principle as the polar transformation.
This analysis was applied to three sets of multi-allelic
data (n>2): pvdhfr codons 57-58-61, pvdhfr 117, and
pvdhps 382-383.
As in the case of bi-allelic data sets, while the coordi-
nate transformation/histogram segmentation approach
better accounted for advancing background due to off-
target hybridization, it is not a bulletproof algorithm
that guarantees 100% accurate diagnosis. Indeed, given
the intrinsic variability of any biological measurement
process it is unlikely such a perfect algorithm exists. A
significant limitation of the heuristic algorithm described
here, at least from a theoretical point of view, is that
independent determination of the diagnostic thresholds
for each locus can lead to a situation in which a given
sample is judged to be positively infected at some but
not all loci, which is an inconsistent result. For example,
the field data analysed here comprised 366 samples,
each of which showed a positive diagnosis for P. vivax
by LDR-FMA [31]. Of these samples, 17, or 5%, were
judged not to have enough net fluorescence signal to be
considered positively infected based on the overall mag-
nitude of the fluorescence vector for all seven loci inter-
rogated. Of the 349 samples that showed a positive
overall infection based on the magnitude histogram ana-
lysis, another 12.6% (44 samples) failed to have a posi-
tive single-allele diagnosis for any allele at one of the
loci, leading to an incomplete haplotype determination.
As a practical matter, in these cases the algorithm
described under Methods was supplemented by censor-
ing the samples with an incomplete haplotype
determination.
A total of 23 alleles were screened simultaneously in
the assay, with the possibility of extending the assay
towards screening more alleles as 100 microspheres can
be detected in the same multiplexed assay on the Bio-
Plex liquid array reader. This high multiplexing capacity
significantly reduces costs associated with diagnosing
complex arrays of SNPs associated with anti-malarial
drug resistance. While it would cost approximately 3
USD to genotype one sample using a real-time PCR
assay screening for only four alleles (TaqMan), the costs
of the PCR-LDR-FMA are similar to screen one sample
for more than 20 alleles. In addition, as multiple loci of
a gene are screened simultaneously, it is possible to
identify new genotypes. If a positive signal is observed at
one locus of the gene, but a negative signal at another,
this would demonstrate the positivity of the PCR, and at
the same time, the presence of a new allele not targeted
by any of the LDR primers present in the reaction. In
this case, it would then be necessary to sequence the
Table 1 Pvdhfr, pvdhps, pvmdr1 genotypes prevalence in P. vivax monoclonal infections
Number of P. vivax monoinfected samples (%)
dhfr genotype (codons 57/58/61-117-173)
wild type:
FST-S-I 37 (52.9)
double mutant type:
FRT-N-I 2 (2.9)
LRT-S-I 10 (14.3)
quadruple mutant type:
LRM-T-I 21 (30.0)
dhps genotype (codons 382/383-553-647)
wild type:
SC-A-A 1 (1.4)
single mutant type:
SC-A-P 69 (98.6)
mdr1 genotype (codon 976)
wild type:
Y 58 (82.9)
mutant type:
F 12 (17.1)
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genotype. Modifications to the LDR-FMA are then easily
achieved by designing new sequence-specific primers.
Due to the wide use of sulphadoxine-pyrimethamine
(SP) to treat falciparum malaria, P. vivax has been
exposed worldwide to this anti-malarial drug. In Papua
New Guinea, SP has been added to 4-aminoquinolines
(CQ and amodiaquine) to treat P. falciparum and P.
vivax malaria since 2000. It is therefore not surprising
that pvdhfr and pvdhps mutant alleles [23,33-36] were
highly prevalent, with 65.6% of infected patients display-
ing a triple mutant dhfr genotype (57L-58R-61M).
Because of a high rate of polyclonal infections (83.3%)
and a mean MOI of 1.99 calculated from pvdhfr geno-
typing results, it is difficult to reconstruct haplotypes
and give more than an estimation of their prevalence.
As shown by the results obtained from monoclonal
infections, the 117T mutation was associated with the
triple mutant haplotype 57L-58R-61M in 100% of the
cases. It is therefore possible to predict an overall rate
of infection (among monoclonal and polyclonal infected
patients) with a quadruple mutant dhfr haplotype to
occur in about 66% of the cases.
In vitro results (using a yeast model to express
PvDHFR) have shown a strong correlation between
mutations in pvdhfr and the amount of drug needed to
inhibit the growth in this system. The 50% inhibitory
concentration (IC50) of pyrimethamine is increased by
100-460 fold for a dhfr double mutant 58R-117N, and
more than 500-fold for a quadruple mutant enzyme
57L-58R-61M-117Ti nc o m p a r i s o nt ot h eI C 5 0m e a -
s u r e df o rt h ew i l d - t y p ee n z y m e[ 2 8 , 3 4 ] .F u r t h e r m o r e ,
the quadruple mutant haplotype has been associated
with in vivo treatment failure after treatment with arte-
sunate-SP in a study conducted in Papua, Indonesia
[37]. Similarly, the quadruple mutant haplotype has
been associated with SP treatment failure when com-
pared to lower mutant parasites (triple mutant to wild
type) [38]. The pvmdr1 Y976F mutation (when found in
combination with pvdhfr mutations) was associated with
treatment failure in a PNG study conducted in 2004-
2005 when P. vivax infected patients were treated with
AQ+SP [39].
Very few reports have been available on the preva-
lence of P. vivax dhfr and dhps mutations in PNG.
From 19 isolates collected in 1998 in the Wosera (East
Sepik Province) [28], only one (5.3%) displayed a double
57L-58Rpvdhfr mutation. In the same study, of 25 iso-
lates collected in 2000 in Liksul (Madang Province),
nine displayed a pvdhfr mutant genotype (six were dou-
ble mutant 57L-58R). More recently, genotyping results
for 94 samples collected in three areas from PNG
(Simbu, East Sepik and Madang provinces) between
2004 and 2005 showed higher prevalence of mutant
genotypes and the appearance of quadruple mutant
parasites (pvdhfr 57L-58R-61M-117T) in the population
[24]. This increase is confirmed here with significantly
higher rates of patients infected with mutant genotypes:
57L was found in 78.4% of the participants, 58R in
83.0%, 61M in 65.9%, 117N/T in 70.8%, versus, respec-
tively, 59.6%, 67.0%, 20.2% and 40.4% from the earlier
s t u d y( p<0 . 0 0 1 ) .D a t af r o mP N Gi s o l a t e so npvdhps
have not been generated; only one isolate from PNG
was previously sequenced, showing a mutation at codon
647 (647P) [40]. As for pvmdr1, the 976F mutation was
f o u n da tap r e v a l e n c eo f3 9 . 4 %[ 2 4 ]a n dr e m a i n sa tt h e
same level here (35.1%) despite known high level of CQ-
SP drug resistance in PNG (51.4% after PCR correction
[41]). It has already been discussed that 4-aminoquino-
line resistance may result from a multigenic process
involving different SNPs and/or gene amplification,
Table 2 Pvdhfr, pvdhps, pvmdr1 genotypes identified in
305 P. vivax infected patients
Number of infected patients (%)
dhfr genotype
57-58-61
FST 223 (73.1)
FRT 28 (9.2)
LRT 116 (38.0)
LRM 200 (65.6)
117
S 260 (85.2)
N 12 (3.9)
T 206 (67.5)
173
I 304 (99.7)
L 1 (0.3)
dhps genotype
382-383
SC 305 (100)
SG 2 (0.7)
CC 2 (0.7)
CG 3 (1.0)
553
A 305 (100)
647
A 5 (1.6)
P 303 (99.3)
mdr1 genotype
976
Y 287 (94.1)
F 107 (35.1)
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Page 9 of 11variation in the level of expression [24,25]; it is therefore
harder to correlate the 976F mutation frequency with an
increase of the in vivo level of drug resistance.
Conclusions
While Papua New Guinea and other malaria-endemic
countries are changing their national malaria treatment
policies, and implementing new treatment strategies, it
will be important to assess the impact of such strategies
on the evolution of P. vivax populations. The new high-
throughput method described here represents a valuable
tool that can be used for local or large-scale screening
of P. vivax molecular markers of drug resistance.
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